Xortx completes positive pre-phase 3 meeting with the us food and drug administration

Calgary, alberta, sept. 19, 2022 (globe newswire) -- xortx therapeutics inc. ("xortx" or the “company”) (nasdaq: xrtx | tsxv: xrtx | frankfurt: anu), a clinical development stage pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce completion of the previously announced type b pre-phase 3 meeting with the us food and drug administration (“fda”) held on september 16, 2022. in advance of this meeting, xortx submitted a “pre-phase-3 briefing package” to the fda on thursday, july 28, 2022 and received responses from, and responded to the fda prior to the meeting.
XRTX Ratings Summary
XRTX Quant Ranking